# Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3

> **NCT02057796** · PHASE4 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 1050 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DEVICE:** Xpert MTB/RIF®, Determine TB LAM, Chest X-ray
- **DRUG:** ART (Atripla, Truvada, Efavirenz, Combivir)
- **DRUG:** Rifampin, isoniazid, pyrazinamide, ethambutol

## Key facts

- **NCT ID:** NCT02057796
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 1050 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057796, "Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02057796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*